
News|Articles|August 30, 2024
Highlights From Psoriasis Awareness Month
Author(s)Kaitlyn Bader, Senior Editor
Throughout the month of August, Dermatology Times covered psoriasis news related to Alumis Inc’s phase 3 trial of ESK-001 for plaque psoriasis, AbbVie’s Science of Skin event, and more.
Advertisement
Advertisement
Psoriasis Awareness Month is celebrated every August to highlight new research, reduce stigmas associated with psoriasis, educate patients about treatment opportunities, and advocate for future enhancements. With more than 125 million patients worldwide affected by psoriasis, clinicians have the opportunity to educate their patients about their skin condition and provide information about new treatments or upcoming clinical trials.1
Related to this article

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

For Healthy Skin Month, a dermatologist discusses winter sun protection, overlooked patients in skin cancer screening, bemotrizinol, and AI in detection.
Advertisement
Advertisement

